

**Performance in Delivering Clinical Research Q1 2014-15  
Time to Target (Commercial Contracts)**

Research Ethics Committee Number	Name of Trial	Target number of patients	Recruitment end date	Trial Status	Target met ?	Comments
10/H0606/69	RO4917838 in stable patients with persistent, predominant negative symptoms of schizophrenia treated with antipsychotics - Protocol No. NN25310	6	08/05/2013	Closed - Follow Up Complete	No	Four participants recruited from six, viewed as successful by the sponsor because this study has proven difficult to recruit to across all UK sites. In addition the projected recruitment target for this site was probably over ambitious.
10/H0604/94	RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia treated with antipsychotics. Protocol No. NN25307	6	30/06/2013	Closed - Follow Up Complete	No	This study has also proven difficult to recruit to across all UK sites. In addition the projected recruitment target for this site was probably over ambitious.
11/SC/0383	Evaluation of the effects of agomelatine (25mg and 50mg) and escitalopram 20mg during 8 weeks on emotional blunting, emotional processing and motivation in healthy male and female volunteers.	64	22/03/2013	Closed - Follow Up Complete	Yes	
12/SC/0213	Interventional randomised, double-blind, parallel-group, placebo-controlled, exploratory study investigating the effects of LuAA21004 on cognition and BOLD fMRI signals in subjects remitted from depression and controls	32	05/04/2013	Closed - Follow Up Complete	No	30 participants were recruited. The study team were unable to recruit the final 2 controls and another UK site (Manchester) agreed to do this. The study recruited the target in the UK. 30 participants of 32 recruited equals 94%
12/SC/0544	A randomised, double-blind, placebo-controlled, dose-ranging, parallel-group, phase 2 study of the safety and efficacy of ABT-126 in the treatment of cognitive deficits in schizophrenia (CDS) in nonsmokers	3	03/01/2014	Closed - In Follow Up	No	Recruited 2 out of 3 patients. This study has proven difficult to recruit to across all UK sites due to strict inclusion criteria.
12/NE/0410	A randomised, placebo-controlled, parallel-group, double-blind, efficacy and safety trial of MK-8931 in subjects with mild to moderate Alzheimer's disease	8	23/12/2016	Open	N/A	
12/EM/0391	A randomised, double blind, placebo controlled, phase 3 study to evaluate the efficacy and safety of once a day, TAK375 (Ramelteon) tablet for sub-lingual administration (TAK375SL tablet) 0.1mg and 0.4mg as an adjunctive therapy in the treatment of acute depressive episodes associated with Bipolar 1 disorder in adult subjects	5	05/11/2014	Open	N/A	
13/SC/0386	Long term safety and efficacy of ABT-126 in subjects with schizophrenia: a double-blind extension study for subjects completing study M10-855	2	31/03/2015	Open	No	Of the 2 participants who were eligible to proceed to the extension study only one continued as the 2nd participant withdrew consent to enter the extension study.

**Performance in Delivering Clinical Research Q1 2014-15  
Time to Target (Commercial Contracts)**

13/NW/0727	A randomised, double-blind, placebo-controlled, single-dose, study of the effects of SEP 363856 and Amisulpride on bold-FMRI signal in healthy male and female volunteers with high or low schizotype characteristics	54	29/05/2015	Open	N/A	
------------	---	----	------------	------	-----	--